Takeda delivering transformative healthcare solutions

One key aspect that sets Takeda apart is its core values, known as Takeda-ism–integrity, fairness, honesty, and perseverance. These values are reflected through actions based on a decision-making framework that prioritises patients, builds trust, strengthens reputation, and develops business sustainably.

Dion Warren – area head of India and Southeast Asia (I-SEA) of Takeda

"We believe in the power of combining global insights with local expertise. In Vietnam, we leverage global knowledge and resources to bring innovative solutions to patients, and collaborate with various stakeholders to meet specific healthcare needs," Warren said.

"Our approach ensures that high-quality medicines and vaccines reach those who need them. Takeda aims to become a trusted biopharmaceutical company that makes a lasting impact on Vietnam’s health and wellbeing, through Takeda-ism and sustainable practices."

Takeda focuses on improving people's lives by researching, developing, and bringing to market innovative medicines and vaccines that are accessible to all–regardless of where they live or their financial means.

"We do this not only by ensuring our medicines and vaccines are available and affordable, but also by collaborating to build capacity within the healthcare system that delivers them," Warren added. "Expanding access to medicines and vaccines sustainably and equitably is embedded in our values and integrated into our sustainability strategy to grow our business."

Takeda's commitment in Vietnam

As a healthcare partner in Vietnam for the past decade, Takeda is dedicated to providing transformative treatments. Improving access to medicines is a key part of its business strategy, and the company believes in public-private partnerships to build sustainable health systems that ensure patients receive effective treatments.

Since 2021, Takeda, in collaboration with the National Center for Global Health and Health under Japan's Ministry of Health, Labour, and Welfare, and the Asthma, Allergy & Clinical Immunology Society of Ho Chi Minh City, has worked to improve the diagnosis and treatment of hereditary angioedema (HAE) in Vietnam. This collaboration has resulted in improved healthcare worker understanding, raised public awareness, and developed guidelines for HAE diagnosis and treatment. The first HAE patient has already received treatment at Hospital 108 in Hanoi.

Since 2022, Takeda has sponsored the Bright Future Fund Scholarship Programme, aimed at raising awareness among haematology cancer patients, connecting doctors, caregivers, and patients, and providing consultation services.

In February 2024, Takeda signed an MoU on rare diseases with the Medical Service Administration of the Ministry of Health, together with Roche, Novartis, and Sanofi, to enhance diagnosis and management in this area. The aim is to improve the quality of rare disease diagnosis and treatment, provide ongoing education for healthcare professionals, and develop policies to ensure the supply and access to treatment drugs.

Since June 2024, Takeda has been working with the National Institute of Hematology and Blood Transfusion to strengthen the capacity of haematology and oncology experts. This includes sharing information on the treatment of haemophilia, in line with the Ministry of Health’s guidelines, and raising awareness of haematological cancers like lymphoma and multiple myeloma.

In May 2024, Takeda's dengue vaccine was approved by the Ministry of Health and is now available in hospitals, clinics, and vaccination centres. This vaccine represents a sustainable solution that complements Vietnam's dengue management and control strategies.

Fighting dengue fever through vaccination

Dengue affects nearly half of the global population, with severe outbreaks across Southeast Asia, including Vietnam. These outbreaks, exacerbated by climate change and urbanisation, place significant economic and public health burdens on affected countries. While preventive measures such as vector control and public education are important, rising dengue cases require an integrated strategy, including vaccination, as recommended by the World Health Organization.

The approval of Takeda’s dengue vaccine marks a significant step in dengue prevention in Vietnam, adding an essential component to existing strategies. Takeda's goal is to improve public health by delivering a safe and effective vaccine to reduce the burden of dengue globally. Takeda’s dengue vaccine has already been approved in over 40 countries, including the European Union, Brazil, Argentina, and several Southeast Asian nations.

In Vietnam, Takeda is committed to making the vaccine accessible nationwide, particularly for remote areas and high-risk groups such as low-income families. Expanding vaccination coverage is a key part of the company's strategy against infectious diseases.

"Recognising the burden dengue places on public health and the economy, expanding vaccination coverage is crucial to our infectious disease strategy," Warren said.

This year’s Rare Disease Day on February 29 celebrated the journeys of patients with rare diseases and their caregivers. With a long-standing presence in Vietnam, Takeda remains committed to supporting patients with rare diseases, reflecting its broader mission to bolster the

For over 10 years, Takeda has been a dedicated healthcare partner in Vietnam, delivering transformative treatments and contributing significantly to public health. The recent approval of its dengue vaccine further strengthens this commitment. Warren spoke to VIR about the company's journey and its plans to bring more innovative medicines to Vietnam.

Takeda's commitment to health equity and access for rare disease community This year's Rare Disease Day, February 29, served as a momentous occasion to celebrate the extraordinary journeys of rare disease patients and their devoted caregivers. Having established a strong presence in the Vietnamese market over many years, Takeda holds steadfast in its commitment to bolstering the wellbeing of the Vietnamese people, especially those afflicted by rare diseases. Than Trong Son, head of Medical Affairs, Takeda Vietnam, delves into Takeda's tireless endeavours and commitment to supporting patients afflicted by rare diseases in the country.

Takeda dengue vaccine approved in Vietnam The Drug Administration of Vietnam (DAV) on May 14 issued a decision approving dengue vaccine of Takeda Pharmaceutical Company Limited, becoming the first dengue vaccine approved in the country for use in individuals from four years of age, regardless of previous dengue exposure and without the need for pre-vaccination testing.

Takeda’s decade of healthcare commitments in Vietnam For over 10 years, Takeda has been a dedicated healthcare partner in Vietnam, delivering transformative treatments and contributing significant value to public health. The recent approval of its dengue vaccine further strengthens this commitment. Dion Warren, Takeda’s area head for India and Southeast Asia, talked to VIR’s Bich Thuy about the company’s journey and its plans to bring more innovative medicines to Vietnam.